Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ultragenyx Pharmaceutical Inc. (RARE)
Price$14.51Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M | $271.0M | $103.7M | $51.5M | $2.6M | $133,000 | — | — | — | — |
| Gross profit | $564.0M | $483.0M | $389.0M | $335.0M | — | — | — | $50.3M | $2.6M | — | — | — | — | — |
| Gross margin | 83.80% | 86.25% | 89.63% | 92.21% | — | — | — | 97.77% | 99.96% | — | — | — | — | — |
| Research & development | $750.0M | $698.0M | $648.0M | $705.8M | $497.2M | $412.1M | $357.4M | $294.0M | $231.6M | $183.2M | $114.7M | $46.0M | $27.8M | $12.6M |
| Operating expenses | $1.10B | $1.02B | $958.0M | $983.9M | — | $601.1M | $527.9M | $422.9M | $331.6M | $248.1M | $147.7M | $56.8M | $32.3M | $16.0M |
| Operating income | −$535.0M | −$536.0M | −$569.0M | −$648.9M | −$381.7M | −$330.1M | −$424.2M | −$371.4M | −$328.9M | −$248.0M | −$147.7M | −$56.8M | −$32.3M | −$16.0M |
| Operating margin | −79.49% | −95.71% | −131.11% | −178.60% | −108.63% | −121.80% | −408.98% | −721.18% | −12,593.49% | −186,471.43% | — | — | — | — |
| EBITDA | −$500.0M | −$500.0M | −$543.0M | −$630.7M | −$368.5M | −$317.9M | −$415.6M | −$351.8M | −$323.1M | −$244.6M | −$146.4M | −$56.1M | −$31.8M | −$15.7M |
| EBITDA margin | −74.29% | −89.29% | −125.12% | −173.59% | −104.86% | −117.28% | −400.75% | −683.24% | −12,370.48% | −183,896.99% | — | — | — | — |
| Net income | −$575.0M | −$569.0M | −$607.0M | −$707.4M | −$454.0M | −$186.6M | −$402.7M | −$197.6M | −$302.1M | −$245.9M | −$145.6M | −$59.8M | −$35.1M | −$16.3M |
| Net profit margin | −85.44% | −101.61% | −139.86% | −194.71% | −129.20% | −68.84% | −388.31% | −383.75% | −11,567.34% | −184,867.67% | — | — | — | — |
| Basic EPSper basic share | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 | -$7.12 | -$3.97 | -$7.12 | -$6.21 | -$3.96 | -$2.25 | -$14.87 | -$14.20 |
| Diluted EPSper diluted share | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 | -$7.12 | -$3.97 | -$7.12 | -$6.21 | -$3.96 | -$2.25 | -$14.87 | -$14.20 |
Owners
Reported shareholders
10.81%of listed shares
BlackRock, Inc.10.65M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.81%10.65M shares |
RTW INVESTMENTS, LP | 7.91%7.8M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 6.89%6.79M shares |
AQR CAPITAL MANAGEMENT LLC | 6.65%6.56M shares |
STATE STREET CORP | 6.25%6.16M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.36%4.3M shares |
TWO SIGMA INVESTMENTS, LP | 3.67%3.62M shares |
SANDS CAPITAL MANAGEMENT, LLC | 3.20%3.16M shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 2.98%2.94M shares |
FRONTIER CAPITAL MANAGEMENT CO LLC | 2.89%2.85M shares |
KAKKIS EMIL D | ≈2.73%2.69M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.62%2.58M shares |
Bellevue Group AG | 2.01%1.98M shares |
D. E. Shaw & Co., Inc. | 1.75%1.73M shares |
Sofinnova Investments, Inc. | 1.74%1.72M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.60%1.58M shares |
GW&K Investment Management, LLC | 1.50%1.48M shares |
MPM BIOIMPACT LLC | 1.44%1.42M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.38%1.36M shares |
MORGAN STANLEY | 1.34%1.32M shares |
Percentages use 98.6M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 | Sanders Corazon (Corsee) D.Director | SellCommon Stock | 2.0K | $25.05 | $50.1K | 21.1K |
| Jun 15, 2026Form 4 · 10b5-1 | Parschauer Karah HerdmanEVP and Chief Legal Officer | SellCommon Stock | 1.9K | $24.62 | $46.8K | 94.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Horn HowardChief Financial Officer | SellCommon Stock | 4.7K | $23.77 | $110.6K | 105.7K |
| May 18, 2026Form 4 · 10b5-1 | SULIMAN SHEHNAAZDirector | SellCommon Stock | 5.7K | $25.12 | $144.2K | 28.0K |
| May 5, 2026Form 4 | Crombez EricEVP and Chief Medical Officer | SellCommon Stock | 344 | $24.96 | $8.6K | 111.2K |
Community posts
Ultragenyx wins FDA approval for its Sanfilippo gene therapy
Ultragenyx ($RARE) received standard FDA approval for FAYUVI, the first approved treatment for Sanfilippo syndrome Type A. The single-infusion gene therapy treats neurological manifestations in pediatric patients with preserved neurodevelop ...
